Close

Natera (NTRA) Announces CMS 2017 CLFS for Aneuploidy And Microdeletion Testing; Sees Impact

Go back to Natera (NTRA) Announces CMS 2017 CLFS for Aneuploidy And Microdeletion Testing; Sees Impact

The Centers For Medicare And Medicaid Services Establishes 2017 Pricing For Aneuploidy And Microdeletion Testing

December 1, 2016 8:00 AM EST

SAN CARLOS, Calif., Dec. 1, 2016 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA announced today that the Centers for Medicare & Medicaid Services (CMS) released final determinations for the 2017 Clinical Lab Fee Schedule (CLFS), which included determinations for both aneuploidy and microdeletion testing described by Current Procedure Terminology (CPT) codes. CMS decided to cross-walk the aneuploidy (81420) and microdeletion (81422) CPT codes to the hereditary colon cancer disorder codes (81435 and 81436, respectively) "based on similarities in function and resource utilization." Both CPT codes will be priced at $796.75,... More